Cargando…
Therapeutic areas: Strategically important diseases of the future
Society and industry—still the only provider of approved medicine—share the desire to treat important diseases. Governments too, since some diseases’ high prevalence affect the economic output of society. Yet the decisions as to which drugs will be developed are strictly in private hands. The risks...
Autores principales: | Bartfai, Tamas, Lees, Graham V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150160/ http://dx.doi.org/10.1016/B978-0-12-407180-3.00005-2 |
Ejemplares similares
-
Alzheimer Drug Trials: Combination of Safe and Efficacious Biologicals to Break the Amyloidosis-Neuroinflammation Vicious Cycle
por: Bartfai, Tamas, et al.
Publicado: (2020) -
Midlife interventions are critical in prevention, delay, or improvement of Alzheimer’s disease and vascular cognitive impairment and dementia
por: Gandy, Sam, et al.
Publicado: (2017) -
Pharma TARP: A Troubled Asset Relief Program for Novel, Abandoned Projects in the Pharmaceutical Industry
por: Bartfai, Tamas, et al.
Publicado: (2011) -
Strategically influencing an uncertain future
por: Govaert, Alain, et al.
Publicado: (2020) -
Strategic Intelligence for the Future 1
por: Dou, Henri
Publicado: (2019)